Header Logo

Connection

GEORGE HUTTON to Humans

Back to Details
This is a "connection" page, showing publications GEORGE HUTTON has written about Humans.
GEORGE HUTTON
Connection Strength
0.266
Humans
  1. Financial and economic costs of healthcare-associated infections in Africa. J Hosp Infect. 2024 Aug; 150:1-8.
    View in: PubMed
    Score: 0.023
  2. Immunopathogenesis, Diagnosis, and Treatment of Multiple Sclerosis: A Clinical Update. Neurol Clin. 2023 02; 41(1):87-106.
    View in: PubMed
    Score: 0.020
  3. Fingolimod-related cryptococcal meningoencephalitis and immune reconstitution inflammatory syndrome in a patient with multiple sclerosis. Mult Scler Relat Disord. 2021 Aug; 53:103072.
    View in: PubMed
    Score: 0.019
  4. The concurrence of multiple sclerosis and glioblastoma. Mult Scler Relat Disord. 2021 May; 50:102877.
    View in: PubMed
    Score: 0.018
  5. Newly diagnosed ganglioglioma in an adult patient with multiple sclerosis. J Neurol Sci. 2016 Oct 15; 369:51-52.
    View in: PubMed
    Score: 0.013
  6. Regulatory effects of interferon-? on osteopontin and interleukin-17 expression in multiple sclerosis. J Interferon Cytokine Res. 2010 Oct; 30(10):751-7.
    View in: PubMed
    Score: 0.009
  7. Pneumocephalus after an epidural steroid injection. Clin Neurol Neurosurg. 2009 Apr; 111(3):309-10.
    View in: PubMed
    Score: 0.008
  8. Heart-shaped lesion secondary to neurosarcoidosis. Arch Neurol. 2008 Oct; 65(10):1388-9.
    View in: PubMed
    Score: 0.008
  9. Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS). Mult Scler. 2026 Jun; 32(7):722-736.
    View in: PubMed
    Score: 0.007
  10. Comparative effectiveness and safety of glatopa and copaxone in patients with multiple sclerosis. Mult Scler Relat Disord. 2025 Dec; 104:106750.
    View in: PubMed
    Score: 0.006
  11. Prevalence of multiple sclerosis and disease-modifying therapy use in older adults in the United States, 2011-2021. Mult Scler. 2025 Nov; 31(13):1595-1599.
    View in: PubMed
    Score: 0.006
  12. Increased Intracranial Pressure in Myelin-Oligodendrocyte Glycoprotein Antibody-Associated Disease. Neurologist. 2025 Jan 01; 30(1):17-22.
    View in: PubMed
    Score: 0.006
  13. Role of magnetic resonance imaging and immunotherapy in treating multiple sclerosis. Annu Rev Med. 2005; 56:273-302.
    View in: PubMed
    Score: 0.006
  14. Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States. Prev Med. 2025 Jan; 190:108180.
    View in: PubMed
    Score: 0.006
  15. Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clin Pharmacol Ther. 2025 Feb; 117(2):561-569.
    View in: PubMed
    Score: 0.006
  16. Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis. Mult Scler Relat Disord. 2024 Nov; 91:105896.
    View in: PubMed
    Score: 0.006
  17. Frequency, characteristics, predictors and treatment of relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Mult Scler Relat Disord. 2024 Jul; 87:105672.
    View in: PubMed
    Score: 0.006
  18. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis. Mult Scler Relat Disord. 2024 May; 85:105539.
    View in: PubMed
    Score: 0.006
  19. Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2023 06; 43(6):473-484.
    View in: PubMed
    Score: 0.005
  20. Health-related quality of life of patients with multiple sclerosis: Analysis of ten years of national data. Mult Scler Relat Disord. 2022 Oct; 66:104019.
    View in: PubMed
    Score: 0.005
  21. FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Mult Scler Relat Disord. 2022 Apr; 60:103703.
    View in: PubMed
    Score: 0.005
  22. Elsberg syndrome following acute immunosuppressive treatment for multiple sclerosis relapse. Mult Scler Relat Disord. 2022 Feb; 58:103498.
    View in: PubMed
    Score: 0.005
  23. Clinical Reasoning: A 57-Year-Old Man With Stepwise Progressive Paraparesis, Sensory Loss, Urinary Retention, and Constipation. Neurology. 2022 02 01; 98(5):e555-e560.
    View in: PubMed
    Score: 0.005
  24. Prescribing of disease modifying agents in older adults with multiple sclerosis. Mult Scler Relat Disord. 2022 Jan; 57:103308.
    View in: PubMed
    Score: 0.005
  25. Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021 Sep; 54:103149.
    View in: PubMed
    Score: 0.005
  26. Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2021 05; 41(5):440-450.
    View in: PubMed
    Score: 0.005
  27. Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records. Mult Scler Relat Disord. 2020 Oct; 45:102334.
    View in: PubMed
    Score: 0.004
  28. Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020 Jun; 26(6):741-749.
    View in: PubMed
    Score: 0.004
  29. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years. Mult Scler Relat Disord. 2020 Aug; 43:102146.
    View in: PubMed
    Score: 0.004
  30. Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data. Res Social Adm Pharm. 2020 Dec; 16(12):1670-1676.
    View in: PubMed
    Score: 0.004
  31. Histogram analysis of apparent diffusion coefficient and fluid-attenuated inversion recovery in discriminating between enhancing and nonenhancing lesions in multiple sclerosis. Clin Imaging. 2020 Jan; 59(1):13-20.
    View in: PubMed
    Score: 0.004
  32. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology. 2017 Feb 28; 88(9):842-852.
    View in: PubMed
    Score: 0.003
  33. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol. 2015 Feb; 72(2):159-69.
    View in: PubMed
    Score: 0.003
  34. IFN-? induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis. J Neuroimmunol. 2012 Jan 18; 242(1-2):39-46.
    View in: PubMed
    Score: 0.002
  35. Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab. Neurology. 2011 Aug 02; 77(5):505-7.
    View in: PubMed
    Score: 0.002
  36. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology. 2009 Feb 10; 72(6):535-41.
    View in: PubMed
    Score: 0.002
  37. Spectrum of pediatric neuromyelitis optica. Pediatrics. 2008 Nov; 122(5):e1039-47.
    View in: PubMed
    Score: 0.002
  38. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data. Mult Scler. 2008 Apr; 14(3):370-82.
    View in: PubMed
    Score: 0.002
  39. Autologous HSCT for advanced MS: is the glass half-empty or really half-full? Brain. 2008 Feb; 131(Pt 2):e89; author reply e90.
    View in: PubMed
    Score: 0.002
  40. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):705-9.
    View in: PubMed
    Score: 0.002
  41. The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis. Neurology. 2004 Dec 14; 63(11 Suppl 5):S3-11.
    View in: PubMed
    Score: 0.001
  42. Costs attributable to AIDS at household level in Chad. AIDS Care. 2004 Oct; 16(7):808-16.
    View in: PubMed
    Score: 0.001
  43. Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis. Mult Scler. 2004 Oct; 10(5):499-506.
    View in: PubMed
    Score: 0.001
  44. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol. 2004 Jul; 152(1-2):126-39.
    View in: PubMed
    Score: 0.001
  45. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. 2004 May; 127(Pt 5):996-1008.
    View in: PubMed
    Score: 0.001
  46. A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis. Clin Ther. 2002 Dec; 24(12):1998-2021.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.